...
首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Quantitative assessment of C-polysaccharide in capsular polysaccharides of Streptococcus pneumoniae by (PNMR)-P-31
【24h】

Quantitative assessment of C-polysaccharide in capsular polysaccharides of Streptococcus pneumoniae by (PNMR)-P-31

机译:(PNMR)-P-31肺炎链球菌肺炎链球菌囊多糖中C-多糖的定量评估

获取原文
获取原文并翻译 | 示例
           

摘要

Capsular polysaccharides of Streptococcus pneumoniae are key components of commercially available anti-pneumococcal vaccines; meanwhile C-polysaccharide is considered an impurity. World Health Organization recommends a strict control over the presence of this biomolecule due to the possibility of introducing an undesired response. An alternative way for assessing this impurity is focused on detect the phosphocholine residues by means of quantitative H-1-NMR. This could be tricky due to the amounts of this substituent may vary generating two C-polysaccharides forms. In this work we propose an improved quantitative NMR methodology based on P-31-NMR for the quantification of C-polysaccharide on capsular polysaccharide preparations. The technique also focuses on phosphocholine but, conversely to above-mentioned methods, allows to discriminate between phosphocholine linked in different positions. The methodology was run on samples of eleven vaccine serotypes, including seven with phosphate groups. From a rational acceptance criterion of 10 wt%, the method allows to quantified from 30 mu g of the impurity in 3 mg of total polysaccharide (1 wt%) with a signal/noise ratio of 16:1. Repeatability and intermediate precision evaluation showed a relative standard deviation of 3.33 % and 8.34 % respectively. Additionally, the method provides information about structural identity of phosphate contained in capsular polysaccharides and C-polysaccharide species. This constitutes a new contribution from the NMR that highlights the power of these techniques for assessing imperative parameters in carbohydrate-based vaccines. (C) 2020 Elsevier B.V. All rights reserved.
机译:肺炎链球菌荚膜多糖是商用抗肺炎球菌疫苗的关键成分;同时,C-多糖被认为是一种杂质。世界卫生组织建议严格控制这种生物分子的存在,因为它可能会引起不希望的反应。评估该杂质的另一种方法是通过定量H-1-NMR检测磷酸胆碱残基。这可能很棘手,因为这种取代基的数量可能不同,生成两种C-多糖形式。在这项工作中,我们提出了一种改进的基于P-31-NMR的定量NMR方法,用于胶囊多糖制剂中C-多糖的定量。该技术也关注磷酸胆碱,但与上述方法相反,它允许区分不同位置连接的磷酸胆碱。该方法是在11种疫苗血清型的样本上进行的,其中包括7种磷酸盐组。从10 wt%的合理接受标准来看,该方法允许以16:1的信噪比从3 mg总多糖(1 wt%)中的30μg杂质进行量化。重复性和中间精密度评估的相对标准偏差分别为3.33%和8.34%。此外,该方法还提供了荚膜多糖和C-多糖种类中所含磷酸盐的结构特征信息。这是核磁共振的一个新贡献,它强调了这些技术在评估基于碳水化合物的疫苗的必要参数方面的威力。(C) 2020爱思唯尔B.V.版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号